 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...101102103104105106107108109110111...132133» |
- | everolimus / Generic mfg.
Enrollment change, Metastases: Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China (clinicaltrials.gov) - Sep 8, 2016
P4, N=30, Recruiting, Sponsor: Novartis Pharmaceuticals
N=20 --> 30
- everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Stroma: Mesenchymal Stromal Cell Therapy in Renal Recipients (clinicaltrials.gov) - Sep 7, 2016
P2, N=70, Recruiting, Sponsor: Leiden University Medical Center
N=20 --> 30 Trial primary completion date: Mar 2016 --> Dec 2017
- ||| everolimus / Generic mfg.
Biomarker, Enrollment closed, Trial primary completion date: PEARL: Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women (clinicaltrials.gov) - Sep 7, 2016
P2, N=130, Active, not recruiting, Sponsor: Jules Bordet Institute
Trial primary completion date: Mar 2016 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Oct 2016
- ||| LCL161 / Novartis, spartalizumab (PDR001) / Novartis
New P1 trial, Combination therapy, PD(L)-1 Biomarker: A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat (clinicaltrials.gov) - Sep 7, 2016
P1, N=350, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Farydak (panobinostat) / Secura Bio
Enrollment change, Trial primary completion date, Combination therapy, Epigenetic controller: Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors (clinicaltrials.gov) - Sep 6, 2016
P1, N=49, Active, not recruiting, Sponsor: National Cancer Centre, Singapore
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Oct 2016 N=40 --> 49 | Trial primary completion date: Dec 2016 --> Jun 2016
- everolimus / Generic mfg.
Trial completion: The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation (clinicaltrials.gov) - Aug 31, 2016
P3, N=18, Completed, Sponsor: Hospital Vall d'Hebron
N=40 --> 49 | Trial primary completion date: Dec 2016 --> Jun 2016 Active, not recruiting --> Completed
- everolimus / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Aug 30, 2016
P2, N=40, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: Jan 2016 --> Jan 2017
- Caprelsa (vandetanib) / Sanofi, Sutent (sunitinib) / Pfizer
Trial primary completion date: A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study (clinicaltrials.gov) - Aug 30, 2016
P=N/A, N=50, Recruiting, Sponsor: Sun Yat-sen University
Trial primary completion date: Jan 2016 --> Jan 2017 Trial primary completion date: May 2015 --> May 2017
- | Sutent (sunitinib) / Pfizer
Trial completion, Enrollment change, Metastases: Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib (clinicaltrials.gov) - Aug 26, 2016
P4, N=29, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: May 2015 --> May 2017 Recruiting --> Completed | N=62 --> 29
- || BNC105 / Bionomics
Trial primary completion date, Combination therapy, Metastases: BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Aug 24, 2016
P2, N=152, Active, not recruiting, Sponsor: Hoosier Cancer Research Network
Recruiting --> Completed | N=62 --> 29 Trial primary completion date: Dec 2015 --> Oct 2016
- ||||||| Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date: PILLAR2: Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy (clinicaltrials.gov) - Aug 24, 2016
P3, N=741, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Oct 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2019 --> Jun 2016
- Archexin (WGI-0201) - Zhejiang Haichang Bio / Tech
Phase classification, Combination therapy, Metastases: Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer (clinicaltrials.gov) - Aug 23, 2016
P1b/2, N=39, Recruiting, Sponsor: Rexahn Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jan 2019 --> Jun 2016 Phase classification: P1/2 --> P1b/2
- || telaglenastat (CB-839) / Calithera
Trial primary completion date, Combination therapy, Metastases: Study of the Glutaminase Inhibitor CB-839 in Solid Tumors (clinicaltrials.gov) - Aug 22, 2016
P1, N=205, Recruiting, Sponsor: Calithera Biosciences, Inc
Phase classification: P1/2 --> P1b/2 Trial primary completion date: Jun 2016 --> Jun 2017
- everolimus / Generic mfg.
Biomarker, Trial completion, Enrollment change, Metastases: NEORAD: Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus (clinicaltrials.gov) - Aug 19, 2016
P2, N=25, Completed, Sponsor: Association Pour La Recherche des Th
Trial primary completion date: Jun 2016 --> Jun 2017 Recruiting --> Completed | N=60 --> 25
- Xalkori (crizotinib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Enrollment open, Metastases: Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma (clinicaltrials.gov) - Aug 17, 2016
P2, N=152, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Recruiting --> Completed | N=60 --> 25 Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
Trial completion, Trial primary completion date: Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator. (clinicaltrials.gov) - Aug 17, 2016
P2, N=2, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Jan 2021 --> Jul 2016
- | Trial completion, Enrollment change: Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors (clinicaltrials.gov) - Aug 16, 2016
P4, N=47, Completed, Sponsor: Hospital do Rim e Hipertensão
Active, not recruiting --> Completed | Trial primary completion date: Jan 2021 --> Jul 2016 Active, not recruiting --> Completed | N=100 --> 47
- || Rituxan (rituximab) / Roche
Trial primary completion date: Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Aug 16, 2016
P1/2, N=70, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | N=100 --> 47 Trial primary completion date: Aug 2016 --> Aug 2017
- || letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Trial primary completion date: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Aug 16, 2016
P2, N=84, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Jul 2016 --> Jul 2017
- ||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed, Trial primary completion date: Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria (clinicaltrials.gov) - Aug 16, 2016
P4, N=200, Active, not recruiting, Sponsor: Helio Tedesco Silva Junior
Trial primary completion date: Jul 2016 --> Jul 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Mar 2016
- everolimus / Generic mfg.
New trial, PD(L)-1 Biomarker, IO biomarker: Analysis of Circulating Tumor Markers in the Blood (ALCINA) (clinicaltrials.gov) - Aug 15, 2016
P=N/A, N=620, Recruiting, Sponsor: Institut Curie
- veliparib (ABT-888) / AbbVie, Mekinist (trametinib) / Novartis, BeiGene, adavosertib (AZD1775) / AstraZeneca
Phase classification, PARP Biomarker, Metastases: MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations (clinicaltrials.gov) - Aug 12, 2016
P=N/A, N=700, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Mar 2016 Phase classification: P2 --> P=N/A
- | everolimus / Generic mfg.
New P4 trial: SCHEDULE Follow Up Visit 5-7 yr (clinicaltrials.gov) - Aug 12, 2016
P4, N=50, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- everolimus / Generic mfg.
Trial primary completion date, IO biomarker, Metastases: A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus (clinicaltrials.gov) - Aug 11, 2016
P2, N=47, Recruiting, Sponsor: European Institute of Oncology
Phase classification: P2 --> P=N/A Trial primary completion date: Jun 2016 --> Jun 2017
- everolimus / Generic mfg., bendamustine / Generic mfg.
Trial primary completion date: Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer (clinicaltrials.gov) - Aug 10, 2016
P1, N=18, Recruiting, Sponsor: University of California, Davis
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: May 2016 --> Dec 2016
- everolimus / Generic mfg.
Trial primary completion date, IO biomarker: Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas (clinicaltrials.gov) - Aug 10, 2016
P0, N=51, Recruiting, Sponsor: New York University School of Medicine
Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: Jun 2016 --> Dec 2018
- || everolimus / Generic mfg.
New P2/3 trial: EVEROST: Topical Everolimus in Patients With Tuberous Sclerosis Complex (clinicaltrials.gov) - Aug 9, 2016
P2/3, N=96, Not yet recruiting, Sponsor: Hospices Civils de Lyon
- || everolimus / Generic mfg.
Trial primary completion date, Combination therapy: HEPHAISTOS: Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients (clinicaltrials.gov) - Aug 9, 2016
P4, N=330, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2016 --> Dec 2018 Trial primary completion date: May 2017 --> Aug 2017
- || Piqray (alpelisib) / Novartis
Trial primary completion date, Metastases: Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors (clinicaltrials.gov) - Aug 8, 2016
P1, N=166, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: May 2017 --> Aug 2017 Trial primary completion date: Dec 2017 --> Apr 2018
- everolimus / Generic mfg.
Trial primary completion date, Combination therapy: Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL (clinicaltrials.gov) - Aug 8, 2016
P1, N=42, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Dec 2017 --> Apr 2018 Trial primary completion date: Aug 2016 --> Aug 2017
- | everolimus / Generic mfg.
New P4 trial, Metastases: Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China (clinicaltrials.gov) - Aug 5, 2016
P4, N=20, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| everolimus / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy: 4EVERLUNG: Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients (clinicaltrials.gov) - Aug 4, 2016
P3, N=130, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2016 --> Aug 2017 Recruiting --> Active, not recruiting | N=232 --> 130 | Trial primary completion date: Feb 2019 --> Jan 2017
- ||| Enrollment closed, Trial primary completion date: MANDELA: A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients (clinicaltrials.gov) - Aug 4, 2016
P4, N=178, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=232 --> 130 | Trial primary completion date: Feb 2019 --> Jan 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Apr 2017
- || Kisqali (ribociclib) / Novartis
Phase classification, Trial primary completion date, Combination therapy, Metastases: Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Aug 3, 2016
P1, N=142, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Apr 2017 Phase classification: P1/2 --> P1 | Trial primary completion date: Nov 2016 --> Jul 2017
- everolimus / Generic mfg.
Enrollment closed: EVACEL: Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors (clinicaltrials.gov) - Aug 3, 2016
P2, N=74, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Phase classification: P1/2 --> P1 | Trial primary completion date: Nov 2016 --> Jul 2017 Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
New trial, Metastases: EVERIMMUN: Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus (clinicaltrials.gov) - Aug 3, 2016
P=N/A, N=112, Recruiting, Sponsor: Centre Hospitalier Universitaire de Besancon
- oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., everolimus / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Metastases: Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer (clinicaltrials.gov) - Jul 29, 2016
P1/2, N=6, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=44 --> 6 | Trial primary completion date: Apr 2017 --> Jul 2016
- veliparib (ABT-888) / AbbVie, Mekinist (trametinib) / Novartis, BeiGene, adavosertib (AZD1775) / AstraZeneca
Trial initiation date, PARP Biomarker, Metastases: MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations (clinicaltrials.gov) - Jul 28, 2016
P2, N=700, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=44 --> 6 | Trial primary completion date: Apr 2017 --> Jul 2016 Initiation date: Mar 2013 --> Dec 2013
- everolimus / Generic mfg.
Enrollment open, Metastases: An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis (clinicaltrials.gov) - Jul 28, 2016
P1/2, N=14, Recruiting, Sponsor: Sunnybrook Health Sciences Centre
Initiation date: Mar 2013 --> Dec 2013 Not yet recruiting --> Recruiting
- |||| serabelisib (MLN1117) / Takeda
Enrollment open, Metastases: MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma (clinicaltrials.gov) - Jul 27, 2016
P2, N=189, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||||| everolimus / Generic mfg., cyclosporine / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. (clinicaltrials.gov) - Jul 25, 2016
P3, N=56, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=75 --> 56 | Trial primary completion date: Sep 2017 --> Jun 2016
- ||| metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Metastases: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Jul 25, 2016
P2, N=62, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=75 --> 56 | Trial primary completion date: Sep 2017 --> Jun 2016 Recruiting --> Active, not recruiting
- | Imbruvica (ibrutinib) / AbbVie, J&J
Phase classification, Combination therapy, Metastases: Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (clinicaltrials.gov) - Jul 22, 2016
P1b/2, N=261, Recruiting, Sponsor: Pharmacyclics
Recruiting --> Active, not recruiting Phase classification: P1/2 --> P1b/2
- lapatinib / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Jul 20, 2016
P2, N=45, Recruiting, Sponsor: University of Kansas Medical Center
Phase classification: P1/2 --> P1b/2 Trial primary completion date: May 2016 --> Jul 2017
- everolimus / Generic mfg.
New trial: Everolimus Modulation of Anti-tumor T CD4 Immune Responses (clinicaltrials.gov) - Jul 20, 2016
P=N/A, N=60, Recruiting, Sponsor: Centre Hospitalier Universitaire de Besancon
- Farydak (panobinostat) / Secura Bio, Sutent (sunitinib) / Pfizer
Trial termination, Combination therapy, Metastases: Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate (clinicaltrials.gov) - Jul 19, 2016
P1/2, N=26, Terminated, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: May 2016 --> Jul 2017 Active, not recruiting --> Terminated; pts off study, PI left institute
- |||| Cabometyx (cabozantinib tablet) / Exelixis
Trial primary completion date, Metastases: METEOR: A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Jul 19, 2016
P3, N=650, Active, not recruiting, Sponsor: Exelixis
Active, not recruiting --> Terminated; pts off study, PI left institute Trial primary completion date: Sep 2015 --> May 2015
- || metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Jul 19, 2016
P2, N=64, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2015 --> May 2015 Trial primary completion date: Oct 2017 --> Oct 2018
- || Trial primary completion date, Combination therapy, Metastases: BOLERO-6: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (clinicaltrials.gov) - Jul 19, 2016
P2, N=317, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2017 --> Oct 2018 Trial primary completion date: Nov 2016 --> Oct 2017
- || ganitumab (AMG 479) / Takeda, ImmunityBio, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date, Combination therapy, Metastases: A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007 (clinicaltrials.gov) - Jul 19, 2016
P1, N=100, Recruiting, Sponsor: Herbert Hurwitz, MD
Trial primary completion date: Nov 2016 --> Oct 2017 Trial primary completion date: Apr 2016 --> Jun 2017